Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥8,640 JPY
Change Today +20.00 / 0.23%
Volume 17.7K
As of 10:25 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

taisho pharmaceutical holdin (4581) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/31/15 - ¥9,240
52 Week Low
10/17/14 - ¥6,780
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TAISHO PHARMACEUTICAL HOLDIN (4581)

Related News

No related news articles were found.

taisho pharmaceutical holdin (4581) Related Businessweek News

No Related Businessweek News Found

taisho pharmaceutical holdin (4581) Details

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, and sells over-the-counter (OTC) drugs and prescription pharmaceuticals in Japan and internationally. The company operates in two segments, Self-Medication Operation Group and Prescription Drug Operation Group. The Self-Medication Operation Group segment manufactures and sells OTC drugs, quasi drugs, and food products, as well as general, medical, and hygiene supplies. Its principal products include the Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatment products, as well as mouthwash, hand wash, and face masks; the RiUP series of hair re-growth treatment products; Livita series of food products for specialized health use, etc.; the Taisho Kampo Ichoyaku series of gastrointestinal treatment products; and the Colac series of laxative products. This segment also engages in real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment manufactures and sells ethical drugs. Its products comprise Clarith, a macrolide antibiotic; ZOSYN, an antibiotic of penicillin with ß-lactamase inhibitor; Palux, a peripheral vasodilator; osteoporosis agents, such as vitamin D3 agent and bisphosphonate antiresorptive agent; Lusefi that is used for type 2 diabetes treatment; Lorcam, a nonsteroidal anti-inflammatory drug; and other inflammation/immune-related products. This segment is also developing various topical and oral products for osteoarthritis, asthma, type 2 diabetes, intermittent claudication, central disorders of hypersomnolence, and depression. The company also offers raw materials for medicines and drugs; employee welfare and benefit services; and supplies health foods and skin care products Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.

6,381 Employees
Last Reported Date: 06/27/14
Founded in 1912

taisho pharmaceutical holdin (4581) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: ¥102.0M
Compensation as of Fiscal Year 2014.

taisho pharmaceutical holdin (4581) Key Developments

Teijin and Taisho Pharmaceutical Holdings Co., Ltd. Sign Sales Agreement for New Anti-Inflammatory Analgesic Patch Formulation

Teijin Limited announced its agreement with Taisho Pharmaceutical Co., Ltd., for the distribution rights in Japan to TT-063, an anti-inflammatory analgesic patch formulation for the anticipated indication of osteoarthritis. The agreement allows TT-063 to be co-marketed by Teijin Pharma Limited.

Taisho Pharmaceutical Holdings Co., Ltd., Q3 2015 Earnings Call, Jan 30, 2015

Taisho Pharmaceutical Holdings Co., Ltd., Q3 2015 Earnings Call, Jan 30, 2015

Taisho Pharmaceutical Holdings Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2014; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2015

Taisho Pharmaceutical Holdings Co., Ltd. reported consolidated earnings results for the nine months ended December 31, 2014. For the period, the company reported net sales of ¥221,759 million against 227,939 million a year ago. Operating income was ¥24,835 million against ¥36,468 million a year ago. Ordinary income was ¥30,891 million against ¥43,816 million a year ago. Net income was ¥19,640 million or ¥242.15 per diluted share compared to ¥27,839 million or ¥343.23 per diluted share for the same period year ago. Income before income taxes and minority interests was ¥31,501 million compared to the ¥43,890 million for the same period year ago. For the fiscal year ending March 31, 2015, the company expects net sales of ¥290,500 million, operating income of ¥29,000 million, ordinary income of ¥37,000 million, net income of ¥24,000 million and net income per share of ¥296.05.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4581:JP ¥8,640.00 JPY +20.00

4581 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Britvic PLC 751.50 GBp +7.00
Dr Pepper Snapple Group Inc $77.24 USD -1.62
Kraft Foods Group Inc $85.87 USD -1.70
Merck KGaA €105.68 EUR +0.71
National Beverage Corp $23.66 USD +0.41
View Industry Companies

Industry Analysis


Industry Average

Valuation 4581 Industry Range
Price/Earnings 28.7x
Price/Sales 2.4x
Price/Book 1.1x
Price/Cash Flow 31.9x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAISHO PHARMACEUTICAL HOLDIN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at